MCID: THR012
MIFTS: 44

Thoracic Cancer

Categories: Cancer diseases

Aliases & Classifications for Thoracic Cancer

MalaCards integrated aliases for Thoracic Cancer:

Name: Thoracic Cancer 12 54 15
Thoracic Neoplasms 43
Thorax Neoplasm 12
Tumor of Thorax 12
Thoracic Tumor 12
Thorax Cancer 12

Classifications:



External Ids:

Disease Ontology 12 DOID:5093
ICD9CM 34 195.1
MeSH 43 D013899
NCIt 49 C3406 C3576
ICD10 32 C76.1
UMLS 71 C0039981 C0153661

Summaries for Thoracic Cancer

Disease Ontology : 12 An organ system cancer located in the thoracic cavity that develops in the different types of cells within the lungs, as well as less common cancers of the esophagus, the trachea, or the chest wall.

MalaCards based summary : Thoracic Cancer, also known as thoracic neoplasms, is related to breast cancer and esophageal cancer. An important gene associated with Thoracic Cancer is MIR199A1 (MicroRNA 199a-1), and among its related pathways/superpathways are TNFR1 Pathway and Measles. The drugs Gemcitabine and Carboplatin have been mentioned in the context of this disorder. Affiliated tissues include thoracic cavity, lung and trachea.

Related Diseases for Thoracic Cancer

Diseases related to Thoracic Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 301)
# Related Disease Score Top Affiliating Genes
1 breast cancer 33.0 TNFSF10 MIR9-1 MIR30A MIR221 MIR21 MIR199A1
2 esophageal cancer 31.4 MIR9-1 MIR30A MIR21 MIR199A1 MIR196A1 MIR145
3 lung cancer 31.3 TNFSF10 MIR9-1 MIR30A MIR221 MIR21 MIR199A1
4 lung cancer susceptibility 3 31.1 TNFSF10 MIR9-1 MIR30A MIR21 MIR199A1 MIR196A1
5 arteries, anomalies of 30.8 MIR9-1 MIR30A MIR221 MIR21 MIR199A1 MIR196A1
6 colorectal cancer 30.8 TNFSF10 MIR9-1 MIR30A MIR221 MIR21 MIR199A1
7 b-cell lymphoma 30.8 MIR21 MIR181A1 MIR17 CDKN1A CASP9 CASP8
8 coronary artery anomaly 30.6 MIR21 MIR199A1 MIR145 MIR126
9 endometriosis 30.5 MIR199A1 MIR145 MIR126 MIR125A
10 mediastinal cancer 11.4
11 smarca4-deficient sarcoma of thorax 11.1
12 chest wall lymphoma 11.1
13 autonomic nervous system neoplasm 10.9 MIR9-1 MIR199A1 MIR196A1 MIR181A1 MIR17 MIR125A
14 peripheral nervous system neoplasm 10.9 MIR9-1 MIR199A1 MIR196A1 MIR181A1 MIR17 MIR125A
15 oral cavity cancer 10.9 TNFSF10 MIR9-1 MIR30A MIR21 MIR199A1 MIR196A1
16 prostate cancer 10.9 TNFSF10 MIR30A MIR221 MIR21 MIR199A1 MIR181A1
17 nervous system cancer 10.9 MIR9-1 MIR30A MIR21 MIR199A1 MIR196A1 MIR181A1
18 myeloma, multiple 10.9 TNFSF10 MIR30A MIR21 MIR199A1 MIR196A1 MIR181A1
19 squamous cell carcinoma, head and neck 10.9 MIR9-1 MIR30A MIR221 MIR21 MIR199A1 MIR196A1
20 lymphoma, non-hodgkin, familial 10.9 MIR9-1 MIR30A MIR21 MIR199A1 MIR196A1 MIR181A1
21 bile duct adenocarcinoma 10.9 MIR9-1 MIR30A MIR21 MIR199A1 MIR181A1 MIR17
22 ovary epithelial cancer 10.9 MIR30A MIR21 MIR199A1 MIR196A1 MIR17 MIR145
23 malignant ovarian surface epithelial-stromal neoplasm 10.9 MIR30A MIR21 MIR199A1 MIR196A1 MIR17 MIR145
24 central nervous system cancer 10.9 MIR9-1 MIR30A MIR21 MIR199A1 MIR196A1 MIR17
25 pharynx cancer 10.9 MIR9-1 MIR30A MIR21 MIR199A1 MIR196A1 MIR17
26 leukemia, chronic lymphocytic 10.9 TNFSF10 MIR9-1 MIR30A MIR221 MIR21 MIR199A1
27 connective tissue cancer 10.9 MIR9-1 MIR21 MIR199A1 MIR196A1 MIR181A1 MIR17
28 hepatocellular carcinoma 10.9 TNFSF10 MIR9-1 MIR30A MIR221 MIR21 MIR199A1
29 eye disease 10.9 TNFSF10 MIR9-1 MIR30A MIR21 MIR199A1 MIR196A1
30 ovarian cancer 10.9 TNFSF10 MIR9-1 MIR30A MIR221 MIR21 MIR199A1
31 autosomal genetic disease 10.9 MIR9-1 MIR21 MIR199A1 MIR196A1 MIR181A1 MIR17
32 esophageal disease 10.9 MIR30A MIR21 MIR199A1 MIR196A1 MIR17 MIR145
33 disease of mental health 10.9 MIR9-1 MIR30A MIR21 MIR199A1 MIR181A1 MIR17
34 renal cell carcinoma, nonpapillary 10.9 TNFSF10 MIR9-1 MIR30A MIR221 MIR21 MIR199A1
35 glucose metabolism disease 10.9 MIR9-1 MIR30A MIR21 MIR199A1 MIR196A1 MIR181A1
36 mouth disease 10.9 MIR9-1 MIR221 MIR21 MIR199A1 MIR196A1 MIR181A1
37 thyroid gland disease 10.9 MIR9-1 MIR30A MIR221 MIR21 MIR199A1 MIR196A1
38 acquired metabolic disease 10.9 MIR9-1 MIR30A MIR21 MIR199A1 MIR196A1 MIR181A1
39 leukemia, chronic myeloid 10.9 TNFSF10 MIR9-1 MIR196A1 MIR17 MIR126 MIR125A
40 bone marrow cancer 10.9 MIR9-1 MIR30A MIR21 MIR199A1 MIR196A1 MIR181A1
41 cervical cancer 10.9 TNFSF10 MIR9-1 MIR30A MIR21 MIR196A1 MIR17
42 biliary tract disease 10.9 MIR9-1 MIR30A MIR199A1 MIR196A1 MIR181A1 MIR17
43 leukemia, acute myeloid 10.9 MIR9-1 MIR30A MIR221 MIR21 MIR199A1 MIR196A1
44 bile duct disease 10.9 MIR9-1 MIR30A MIR199A1 MIR196A1 MIR181A1 MIR17
45 bladder cancer 10.9 TNFSF10 MIR9-1 MIR221 MIR21 MIR17 MIR145
46 leukocyte disease 10.9 MIR9-1 MIR30A MIR21 MIR199A1 MIR196A1 MIR181A1
47 immune system disease 10.9 MIR9-1 MIR30A MIR221 MIR21 MIR199A1 MIR196A1
48 pancreatic cancer 10.9 TNFSF10 MIR30A MIR221 MIR21 MIR199A1 MIR196A1
49 connective tissue disease 10.9 MIR9-1 MIR30A MIR221 MIR21 MIR199A1 MIR196A1
50 central nervous system disease 10.9 MIR9-1 MIR30A MIR221 MIR21 MIR199A1 MIR196A1

Graphical network of the top 20 diseases related to Thoracic Cancer:



Diseases related to Thoracic Cancer

Symptoms & Phenotypes for Thoracic Cancer

Drugs & Therapeutics for Thoracic Cancer

Drugs for Thoracic Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 96)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Gemcitabine Approved Phase 3 95058-81-4 60750
2
Carboplatin Approved Phase 3 41575-94-4 10339178 498142 38904
3
leucovorin Approved Phase 3 58-05-9 6006 143
4
Pemetrexed Approved, Investigational Phase 3 150399-23-8, 137281-23-3 446556 60843
5
Vinorelbine Approved, Investigational Phase 3 71486-22-1 60780 44424639
6
Docetaxel Approved, Investigational Phase 3 114977-28-5 148124
7
Paclitaxel Approved, Vet_approved Phase 3 33069-62-4 36314
8
Folic acid Approved, Nutraceutical, Vet_approved Phase 3 59-30-3 6037
9 Anti-Infective Agents Phase 3
10 Antiviral Agents Phase 3
11 Antimetabolites Phase 3
12 Immunosuppressive Agents Phase 3
13 Folic Acid Antagonists Phase 3
14 Vitamin B9 Phase 3
15 Vitamin B Complex Phase 3
16 Folate Phase 3
17
Erlotinib Hydrochloride Phase 3 183319-69-9 176871
18 Protein Kinase Inhibitors Phase 3
19 Immunologic Factors Phase 3
20 Antibodies, Monoclonal Phase 3
21 Immunoglobulins Phase 3
22 Antibodies Phase 3
23 Albumin-Bound Paclitaxel Phase 3
24 Antimitotic Agents Phase 3
25
Cisplatin Approved Phase 2 15663-27-1 84093 441203 2767
26
Durvalumab Approved, Investigational Phase 2 1428935-60-7
27
nivolumab Approved Phase 1, Phase 2 946414-94-4
28
Midazolam Approved, Illicit Phase 1, Phase 2 59467-70-8 4192
29
Budesonide Approved Phase 2 51333-22-3 63006 5281004
30
Atezolizumab Approved, Investigational Phase 2 1380723-44-3
31
Tyrosine Approved, Investigational, Nutraceutical Phase 1, Phase 2 60-18-4 6057
32 Cola Phase 1, Phase 2
33 Hormone Antagonists Phase 2
34 Hormones Phase 2
35 Anti-Asthmatic Agents Phase 2
36 Respiratory System Agents Phase 2
37 Anti-Inflammatory Agents Phase 2
38 Autonomic Agents Phase 2
39 Bronchodilator Agents Phase 2
40 glucocorticoids Phase 2
41
Apatinib Phase 1, Phase 2 811803-05-1
42 Imatinib Mesylate Phase 2 220127-57-1 123596
43 glutamine Phase 1, Phase 2
44
Azacitidine Approved, Investigational Phase 1 320-67-2 9444
45
Sunitinib Approved, Investigational Phase 1 341031-54-7, 557795-19-4 5329102
46
Dasatinib Approved, Investigational Phase 1 302962-49-8 3062316
47
Exemestane Approved, Investigational Phase 1 107868-30-4 60198
48
Sirolimus Approved, Investigational Phase 1 53123-88-9 5284616 6436030 46835353
49
Cetuximab Approved Phase 1 205923-56-4 56842117 2333
50
Everolimus Approved Phase 1 159351-69-6 6442177 70789204

Interventional clinical trials:

(show top 50) (show all 91)
# Name Status NCT ID Phase Drugs
1 Pioneering Pre- and Post-Operative Integrative Care to Improve Thoracic Cancer Quality of Care: The Thoracic Peri-Operative Integrative Surgical Care Evaluation (POISE) Trial- Stage I Recruiting NCT02845479 Phase 4
2 A Randomized, Double-blind, Placebo-controlled in Parallel, Multicenter Phase III Trial of Recombinant Human Apo-2 Ligand for Injection(Dulanermin for Injection)in the Treatment of Advanced Non-small Cell Lung Cancer Unknown status NCT03083743 Phase 3
3 A Randomized, Controlled Phase III Trial to Evaluate the Efficacy of Elortinib vs Gefitinib in Advanced Non-small-cell Lung Cancer With EGFR Exon 19 or 21 Mutations Completed NCT01024413 Phase 3 erlotinib;gefitinib
4 Phase III Comparison of Postoperative 3D Conform Radiotherapy After Chemotherapy and Chemotherapy Alone in Patients With Completely Resected Stage IIIA(N2) Non-small Cell Lung Cancer Recruiting NCT00880971 Phase 3
5 A Phase III, Randomized, Open-Label, Multi-center Study of SHR-1210(Anti-PD-1 Antibody) in Combination With Pemetrexed and Carboplatin as First Line Therapy in Subjects With Advanced/Metastatic Non-squamous Non-small Cell Lung Cancer Recruiting NCT03134872 Phase 3 Carboplatin;Pemetrexed
6 Randomized Phase III Multicenter Trial of Customized Chemotherapy Versus Standard of Care for1st Line Treatment of Elderly Patients With Advanced Non-Small-Cell Lung Cancer Recruiting NCT03402048 Phase 3 Carboplatin;Gemcitabine;Pemetrexed;Docetaxel;Vinorelbine
7 Comparison Study of Post-operative Pain and Quality of Life Between Subxiphoid and Intercostal Vedio-assisted Thoracic Surgery for Radical Lung Cancer Resection Recruiting NCT03331588 Phase 3
8 Postoperative Pain and Quality of Life for Patients Undergoing Mediastinal Tumor Resection by Subxiphoid and Intercostal VATS:A Randomized Controlled Trial Recruiting NCT03521986 Phase 3
9 A Phase III Randomized, Open-Label Clinical Trial of BBI-608 Plus Weekly Paclitaxel Versus Weekly Paclitaxel Alone in Patients With Advanced, Previously Treated, Non-Squamous Non-Small Cell Lung Cancer Terminated NCT02826161 Phase 3 Napabucasin;Paclitaxel
10 Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multi-Center, Two-Part Study of Patritumab (U3-1287) In Combination With Erlotinib in EGFR Wild-type Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) Who Have Progressed on at Least One Prior Systemic Therapy Terminated NCT02134015 Phase 3 Patritumab;Erlotinib;Placebo
11 A Phase 1b/2 Study of AV-299 (Formerly SCH 900105) in Combination With Gefitinib in Asian Subjects With Non-Small Cell Lung Cancer (P06162) Completed NCT01039948 Phase 1, Phase 2 Gefitinib
12 The Use of Multiple Respiration-Correlated Cone Beam CT Scans to Reduce Target Positioning Errors in Radiotherapy Treatment of Thoracic Cancer. Completed NCT00722605 Phase 1, Phase 2
13 A Feasibility and Biomarker Study to Evaluate Necitumumab in the Neoadjuvant Setting With Gemcitabine and Cisplatin in Surgically Resectable Squamous Lung Cancer Completed NCT03574818 Phase 2 Necitumumab-Gemcitabine-Cisplatin
14 A Phase II Study of Erlotinib (Tarceva) and Hypofractionated Thoracic Radiotherapy for Patients With Advanced or Inoperable Non-Small-Cell Lung Cancer Completed NCT00983307 Phase 2 Erlotinib
15 Local Non-salvage Radiotherapy for Synchronous Oligometastatic Non-small-cell Lung Cancer :A Multicenter,Randomized,Controlled,Phase 2 Study. Recruiting NCT03119519 Phase 2 No Local Definitive Radiotherapy
16 A Randomized Phase 2 Trial of Durvalumab (MEDI4736) With or Without SBRT in Clinical Stage I, II, and IIIA Non-small Cell Lung Cancer (NSCLC) Recruiting NCT02904954 Phase 2 Durvalumab
17 A Safety and Efficacy Study of CT-Guided Adaptive Radiation Therapy With Anti-PD-1 Antibody Adjuvant Immunotherapy in Patients With Thoracic Cancer (CARTAI) Recruiting NCT03732430 Phase 2 IBI308
18 A Phase 1b/2, Open-Label, Multicenter Dose-Escalation and Dose-Expansion Study of the Combination of RMC-4630 and Cobimetinib in Adult Participants With Relapsed/Refractory Solid Tumors With Specific Genomic Aberrations Recruiting NCT03989115 Phase 1, Phase 2 RMC-4630;Cobimetinib
19 Phase 1/2 Study to Evaluate the Safety and Preliminary Activity of Nivolumab in Combination With Vorolanib in Patients With Refractory Thoracic Tumors Recruiting NCT03583086 Phase 1, Phase 2 VEGFR/PDGFR Dual Kinase Inhibitor X-82
20 A Phase 1/2 Study of the Highly-selective RET Inhibitor, BLU-667, in Patients With Thyroid Cancer, Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumors Recruiting NCT03037385 Phase 1, Phase 2 pralsetinib (BLU-667)
21 A Phase 1/2 Study of the Oral RET Inhibitor LOXO 292 in Pediatric Patients With Advanced RET-Altered Solid or Primary Central Nervous System Tumors Recruiting NCT03899792 Phase 1, Phase 2 LOXO-292
22 A Phase 1/2, Open-Label, Multi-Center, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of TPX-0005 in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements (TRIDENT-1) Recruiting NCT03093116 Phase 1, Phase 2 Oral repotrectinib (TPX-0005)
23 A Phase 1/2 Study of Oral LOXO-292 in Patients With Advanced Solid Tumors, Including RET Fusion-Positive Solid Tumors, Medullary Thyroid Cancer, and Other Tumors With RET Activation (LIBRETTO-001) Recruiting NCT03157128 Phase 1, Phase 2 LOXO-292
24 Prophylactic Inhaled Steroids to Reduce Radiation Pneumonitis Frequency and Severity in Non-small Cell Lung Cancer Patients Recruiting NCT03803787 Phase 2 Inhaled budesonide
25 One-arm Exploratory Study on the Efficacy and Safety of Apatinib Combined With SHR-1210 Injection (PD-1 Antibody) in the Treatment of Removable IB-IIIA Non-small Cell Lung Cancer Not yet recruiting NCT04133337 Phase 1, Phase 2 Apatinib;SHR-1210
26 A Randomized, Controlled Phase II Clinical Trial of Apatinib in Combination With EGFR-TKI Versus EGFR-TKI for Non-squamous, Non-small Cell Lung Cancer(NSCLC) With T790M-negative After the Failure of EGFR-TKI Therapy Not yet recruiting NCT03389256 Phase 2 Apatinib;EGFR-TKI
27 Phase II Study to Evaluate the Efficacy and Safety of Atezolizumab in Subjects With Unresectable or Advanced Malignant Pleural Mesothelioma Who Experienced Progression on Platinum-Based Chemotherapy Not yet recruiting NCT03786419 Phase 2 Atezolizumab
28 The Effects of Whole Food Intervention on Mucositis in Patients Treated for Thoracic Cancer With Radiation With or Without Chemotherapy Terminated NCT02575391 Phase 1, Phase 2
29 A Multicenter, Phase 2 Study of Gemcitabine-Carboplatin Plus Necitumumab in Chemotherapy-Naïve Patients With Locally Advanced or Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC) Withdrawn NCT02941601 Phase 2 Necitumumab;Gemcitabine;Carboplatin
30 Phase I Study of Inhaled Vidaza® in Patients With Advanced NSCLC Unknown status NCT02009436 Phase 1 Azacitidine
31 A Phase IB, Open-Label, Safety Study of the Combination of Sunitinib and Radiation for the Treatment of Patients With Cancer Completed NCT00437372 Phase 1 Sunitinib
32 STM-01: Phase I EffTox Study of Aurora A Kinase Inhibitor Alisertib (MLN8237) Given in Combination With Selective VEGFR Inhibitor Pazopanib (Votrient) for Therapy of Solid Tumors Completed NCT01639911 Phase 1 Alisertib;Pazopanib
33 Pilot Study of Online, Adaptive MRI-Guided SBRT for Unresectable Primary or Oligometastatic Central Thorax and Abdominal Malignancies Completed NCT02264886 Phase 1
34 A Phase 1 Cardiac Safety Study of Entinostat in Men and Women With Advanced Solid Tumors Completed NCT02897778 Phase 1 Entinostat
35 Phase I Trial Evaluating Safety and Tolerability of the Irreversible Epidermal Growth Factor Receptor Inhibitor Afatinib (BIBW 2992) in Combination With the SRC Kinase Inhibitor Dasatinib for Patients With Non-small Cell Lung Cancer (NSCLC) Completed NCT01999985 Phase 1 Dasatinib - 1A;Afatinib - 1A;Dasatinib - 1B;Afatinib - 1B
36 A Phase I Study to Assess the Food Effect on the Pharmacokinetics of Entinostat in Postmenopausal Women With Locally Recurrent or Metastatic ER+ Breast Cancer and Men and Women With Progressive Non-Small Cell Lung Cancer Completed NCT01594398 Phase 1 entinostat;entinostat;Erlotinib;Erlotinib;Exemestane;Exemestane
37 A Phase 1, Open-Label, Multicenter, Dose-Escalation Study of RMC-4630 Monotherapy in Adult Participants With Relapsed/Refractory Solid Tumors Recruiting NCT03634982 Phase 1 RMC-4630
38 A Pilot Study of FDG-PET Variability to Establish Biology-Guided Treatment Planning Feasibility for Stereotactic Body Radiation Therapy Recruiting NCT03493789 Phase 1 Fludeoxyglucose F-18
39 A Phase I Trial of Bevacizumab, Temsirolimus Alone and in Combination With Valproic Acid, or Cetuximab in Patients With Advanced Malignancy and Other Indications Recruiting NCT01552434 Phase 1 Temsirolimus;Valproic Acid
40 Phase I Dose Escalation of pAlliative Radiotherapy With Anti-PD1 Antibody Pembrolizumab in Thoracic Tumours Recruiting NCT02587455 Phase 1 Pembrolizumab
41 A Phase 1, Randomized, Open-Label, Continuation Study of Entinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumors (SNDX-275-0141, MK3475-460/KEYNOTE-460) Active, not recruiting NCT02909452 Phase 1 Entinostat;Pembrolizumab
42 A Multimodality Image-guided System for Peripheral Lung Cancer Diagnosis and Therapy Active, not recruiting NCT02111824 Phase 1 Indocyanine Green (ICG)
43 Intratumoral Genetic Therapy for Lung Cancer Terminated NCT01574222 Phase 1
44 Prospect Study to Evaluate Clinical, Dosimetrical, Functional, Biological and Genetic Factors in Predicting Chemo-Radiotherapy Induced Lung and Esophagus Injury Unknown status NCT00631839
45 Monitoring Radiobiological Effects in Thoracic Malignancy by Using Myocardial Perfusion Scan: Correlation Between Radiotherapy Dose Distribution, Myocardial Perfusion, Cardiac Function, Serum Biomarkers and Clinical Prognosis. Unknown status NCT01913769
46 SPECTAlung: Screening Patients With Thoracic Tumors for Efficient Clinical Trial Access Unknown status NCT02214134
47 Oncologic Therapy Support Via Means of a Dedicated Mobile App - a Prospective Feasibility Evaluation Unknown status NCT03168048
48 Assessment of Postoperative Lymphopenia as Risk Factor for Postoperative Infections: EVALYMPH Study Unknown status NCT02799251
49 Development and Feasibility of a Lung Cancer Nurse Model During Early Treatment: a Phase II Study Unknown status NCT02362204
50 Radiotherapeutic Tumor Response and Normal Tissue Effect in Treating Thoracic Malignancy : as Comparing With Free-breathing Non-gating Methods. Unknown status NCT02063633

Search NIH Clinical Center for Thoracic Cancer

Cochrane evidence based reviews: thoracic neoplasms

Genetic Tests for Thoracic Cancer

Anatomical Context for Thoracic Cancer

The Foundational Model of Anatomy Ontology organs/tissues related to Thoracic Cancer:

19
Thoracic Cavity

MalaCards organs/tissues related to Thoracic Cancer:

40
Lung, Trachea, Thyroid, Breast, B Cells, Heart, Testes

Publications for Thoracic Cancer

Articles related to Thoracic Cancer:

(show top 50) (show all 219)
# Title Authors PMID Year
1
Induction of apoptosis of lung and esophageal cancer cells treated with the combination of histone deacetylase inhibitor (trichostatin A) and protein kinase C inhibitor (calphostin C). 54 61
15632825 2005
2
Psychosocial interventions for informal caregivers of lung cancer patients: A systematic review. 61
31701588 2020
3
Short-term integrated rehabilitation for people with newly diagnosed thoracic cancer: a multi-centre randomized controlled feasibility trial. 61
31786963 2020
4
Positive association between heart dosimetry parameters and a novel cardiac biomarker, solubleST-2, in thoracic cancer chest radiation. 61
31923333 2020
5
"Openness" personality trait associated with benefit from a non-pharmacological breathlessness intervention in people with intra-thoracic cancer: an exploratory analysis. 61
32006612 2020
6
EURACAN/IASLC Proposals for Updating the Histologic Classification of Pleural Mesothelioma: Towards a More Multidisciplinary Approach. 61
31546041 2020
7
Evaluation of the effect of user-guided deformable image registration of thoracic images on registration accuracy among users. 61
32014379 2020
8
Outpatient palliative care and thoracic medical oncology: Referral criteria and clinical care pathways. 61
31704278 2020
9
Correlation of prechemotherapy urinary megalin ectodomain (A-megalin) levels with the development of cisplatin-induced nephrotoxicity: a prospective observational study. 61
31791266 2019
10
Aortoesophageal fistula: review of trends in the last decade. 61
31844987 2019
11
[Perioperative Venous Thromboembolism (VTE) Prophylaxis in Thoracic Cancer Patients: Chinese Experts Consensus - Interpretation of Screening of High-risk Patients]. 61
31874668 2019
12
[Perioperative Venous Thromboembolism (VTE) Prophylaxis in Thoracic Cancer Patients: Chinese Experts Consensus - Interpretation of Perioperative Hypercoagulable State]. 61
31874669 2019
13
[Perioperative Venous Thromboembolism (VTE) Prophylaxis in Thoracic Cancer Patients: Chinese Experts Consensus - Interpretation of Application Prospect of Direct Oral Anticoagulant]. 61
31874670 2019
14
[Perioperative Venous Thromboembolism (VTE) Prophylaxis in Thoracic Cancer Patients: Chinese Experts Consensus - Interpretation of Clinical Significance of D-dimer]. 61
31874671 2019
15
[Perioperative Venous Thromboembolism (VTE) Prophylaxis in Thoracic Cancer Patients: Chinese Experts Consensus - Interpretation of Epidemiological Characteristics]. 61
31874667 2019
16
Prophylactic effect of rikkunshito, an herbal medicine, for chemotherapy-induced nausea in thoracic cancer patients receiving carboplatin-based chemotherapy. 61
31685089 2019
17
Holistic Needs of People with Thoracic Cancer Identified by the Sheffield Profile for Assessment and Referral to Care Questionnaire©. 61
30848688 2019
18
Frequency of low-grade adverse events and quality of life during chemotherapy determine patients' judgement about treatment in advanced-stage thoracic cancer. 61
30690684 2019
19
Superior vena cava syndrome: endovascular management. 61
31616492 2019
20
Effect of complementary Integrative Oncology on anxiety, depression and quality of life in thoracic cancer patients: A pilot study. 61
31383444 2019
21
Clinical trial protocol of doublet therapy and olanzapine for carboplatin-induced nausea and vomiting in patients with thoracic cancer: a multicentre phase II trial. 61
31278102 2019
22
AAR-RT - A system for auto-contouring organs at risk on CT images for radiation therapy planning: Principles, design, and large-scale evaluation on head-and-neck and thoracic cancer cases. 61
30831357 2019
23
Technical Note: Density correction to improve CT number mapping in thoracic deformable image registration. 61
30896047 2019
24
Efficacy and tolerance of thoracic radiotherapy in the oldest old patients: A case series. 61
31062737 2019
25
Holistic services for people with advanced disease and chronic breathlessness: a systematic review and meta-analysis. 61
30498004 2019
26
Efficacy of radiofrequency ablation and microwave ablation in the treatment of thoracic cancer: A systematic review and meta-analysis. 61
30677240 2019
27
Radiosensitivity nomogram based on circulating neutrophils in thoracic cancer. 61
30693787 2019
28
Correction: Evaluation of lung toxicity risk with computed tomography ventilation image for thoracic cancer patients. 61
31774868 2019
29
Why Be One Protein When You Can Affect Many? The Multiple Roles of YB-1 in Lung Cancer and Mesothelioma. 61
31632972 2019
30
Haplodeletion of Follistatin-Like 1 Attenuates Radiation-Induced Pulmonary Fibrosis in Mice. 61
30171878 2019
31
A longitudinal study of muscle strength and function in patients with cancer cachexia. 61
29860710 2019
32
PACE: A Probabilistic Atlas for Normal Tissue Complication Estimation in Radiation Oncology. 61
30918837 2019
33
Radiotherapy in palliation of thoracic tumors: a phase I-II study (SHARON project). 61
30298381 2018
34
Thalidomide (THD) alleviates radiation induced lung fibrosis (RILF) via down-regulation of TGF-β/Smad3 signaling pathway in an Nrf2-dependent manner. 61
30339882 2018
35
The Role of Yes-Associated Protein (YAP) in Regulating Programmed Death-Ligand 1 (PD-L1) in Thoracic Cancer. 61
30544524 2018
36
Systemic Therapy in Advanced Thymic Epithelial Tumors: Insights from the RYTHMIC Prospective Cohort. 61
30138763 2018
37
Physician Empathy Interacts with Breaking Bad News in Predicting Lung Cancer and Pleural Mesothelioma Patient Survival: Timing May Be Crucial. 61
30336582 2018
38
[Perioperative Venous Thromboembolism (VTE) Prophalaxis 
in Thoracic Cancer Patients: Chinese Experts Consensus]. 61
30309425 2018
39
Evaluation of a Dedicated Tobacco Cessation Support Service for Thoracic Cancer Center Patients. 61
29278577 2018
40
Naturopathic Oncology Care for Thoracic Cancers: A Practice Survey. 61
29558830 2018
41
Associations of Source-apportioned Fine Particles with Cause-specific Mortality in California. 61
29889687 2018
42
Within and between day repeatability of the incremental shuttle walking test in patients with thoracic cancer. 61
29957278 2018
43
Changing health behaviour with rehabilitation in thoracic cancer: A systematic review and synthesis. 61
29476566 2018
44
Development and evaluation of screening dysphagia tools for observational studies and routine care in cancer patients. 61
30623085 2018
45
Principal component analysis-based imaging angle determination for 3D motion monitoring using single-slice on-board imaging. 61
29635762 2018
46
The diagnostic value of tissue button technique for specimen accusation during endobronchial ultrasound-guided transbronchial fine-needle aspiration. 61
29124891 2018
47
Treatment of Malignant Pleural Mesothelioma: American Society of Clinical Oncology Clinical Practice Guideline. 61
29346042 2018
48
Feasibility of endobronchial ultrasound transbronchial needle aspiration for massively parallel next-generation sequencing in thoracic cancer patients. 61
29656758 2018
49
An Observational Study for Knowing the Compliance of Patients Scheduled for Major Abdominal and Thoracic Cancer Surgeries in a Single Specialty Center. 61
29962633 2018
50
Palliative Care Utilization among Patients Admitted for Gastrointestinal and Thoracic Cancers. 61
29100002 2018

Variations for Thoracic Cancer

Expression for Thoracic Cancer

Search GEO for disease gene expression data for Thoracic Cancer.

Pathways for Thoracic Cancer

Pathways related to Thoracic Cancer according to GeneCards Suite gene sharing:

(show all 30)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.87 TNFSF10 CDKN1A CASP9 CASP8 CASP6 BCL2
2
Show member pathways
12.74 TNFSF10 CDKN1A CASP9 CASP8 BCL2
3
Show member pathways
12.7 TNFSF10 CDKN1A CASP9 CASP8 CASP6 BCL2
4
Show member pathways
12.61 CDKN1A CASP9 CASP8 CASP6 BCL2
5
Show member pathways
12.5 TNFSF10 CASP9 CASP8 CASP6 BCL2
6
Show member pathways
12.36 CASP9 CASP8 CASP6 BCL2
7
Show member pathways
12.14 TNFSF10 H2AC18 CASP8 BCL2
8
Show member pathways
12.11 CASP9 CASP8 CASP6 BCL2
9 12.1 TNFSF10 CASP9 CASP8 CASP6 BCL2
10 12.01 CASP9 CASP8 CASP6 BCL2
11
Show member pathways
11.93 CASP9 CASP8 CASP6 BCL2
12 11.93 MIR9-1 MIR30A MIR221 MIR21 MIR199A1 MIR181A1
13
Show member pathways
11.91 TNFSF10 CDKN1A CASP9 CASP8 CASP6 BCL2
14
Show member pathways
11.87 MIR221 MIR181A1 MIR17 CDKN1A CASP9 CASP8
15 11.79 CDKN1A CASP9 BCL2
16
Show member pathways
11.72 CASP9 CASP8 CASP6
17 11.72 MIR30A MIR17 CASP9 CASP6
18
Show member pathways
11.7 CASP9 CASP8 CASP6 BCL2
19 11.69 CDKN1A CASP6 BCL2
20 11.62 CDKN1A CASP9 CASP8 BCL2
21 11.48 TNFSF10 CDKN1A BCL2
22
Show member pathways
11.45 CASP9 CASP8 CASP6
23 11.4 MIR221 MIR181A1 MIR145 CDKN1A
24 11.39 TNFSF10 CASP9 CASP8
25
Show member pathways
11.34 CASP9 CASP8 BCL2
26 11.33 CDKN1A CASP9 CASP8 BCL2
27 11.22 CASP9 CASP8 CASP6 BCL2
28 11.14 MIR9-1 MIR221 MIR199A1 MIR181A1
29
Show member pathways
11.03 TNFSF10 CDKN1A BCL2
30 10.76 MIR199A1 MIR145

GO Terms for Thoracic Cancer

Cellular components related to Thoracic Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.32 TNFSF10 MIR30A MIR221 MIR21 MIR199A1 MIR181A1

Biological processes related to Thoracic Cancer according to GeneCards Suite gene sharing:

(show all 19)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of apoptotic process GO:0043066 9.96 MIR30A MIR221 MIR21 CDKN1A BCL2
2 negative regulation of cell proliferation GO:0008285 9.91 MIR9-1 MIR221 MIR21 CDKN1A BCL2
3 regulation of apoptotic process GO:0042981 9.87 CASP9 CASP8 CASP6 BCL2
4 positive regulation of protein kinase B signaling GO:0051897 9.73 MIR221 MIR21 MIR199A1 MIR126
5 activation of cysteine-type endopeptidase activity involved in apoptotic process GO:0006919 9.72 TNFSF10 CASP9 CASP8
6 negative regulation of G1/S transition of mitotic cell cycle GO:2000134 9.67 MIR21 CDKN1A BCL2
7 positive regulation of angiogenesis GO:0045766 9.62 MIR30A MIR21 MIR199A1 MIR126
8 negative regulation of reactive oxygen species biosynthetic process GO:1903427 9.58 MIR21 MIR181A1
9 negative regulation of osteoblast proliferation GO:0033689 9.58 MIR9-1 BCL2
10 positive regulation of vascular smooth muscle cell proliferation GO:1904707 9.58 MIR221 MIR21 MIR17
11 negative regulation of gene expression GO:0010629 9.55 MIR21 MIR181A1 MIR17 MIR125A CDKN1A
12 positive regulation of cardiac muscle hypertrophy in response to stress GO:1903244 9.54 MIR199A1 MIR17
13 positive regulation of blood vessel endothelial cell migration GO:0043536 9.54 MIR30A MIR221 MIR126
14 positive regulation of metalloendopeptidase activity GO:1904685 9.52 MIR21 MIR17
15 miRNA mediated inhibition of translation GO:0035278 9.5 MIR9-1 MIR30A MIR221 MIR21 MIR181A1 MIR17
16 negative regulation of vascular associated smooth muscle cell apoptotic process GO:1905460 9.48 MIR21 MIR17
17 response to cobalt ion GO:0032025 9.46 CASP9 CASP8
18 negative regulation of cardiac muscle cell apoptotic process GO:0010667 9.43 MIR21 MIR199A1 MIR145
19 gene silencing by miRNA GO:0035195 9.4 MIR9-1 MIR30A MIR221 MIR21 MIR199A1 MIR196A1

Molecular functions related to Thoracic Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cysteine-type endopeptidase activity GO:0004197 9.5 CASP9 CASP8 CASP6
2 mRNA binding involved in posttranscriptional gene silencing GO:1903231 9.4 MIR9-1 MIR30A MIR221 MIR21 MIR199A1 MIR196A1
3 RNA polymerase II complex binding GO:0000993 9.33 MIR145 MIR126 MIR125A
4 cysteine-type endopeptidase activity involved in apoptotic signaling pathway GO:0097199 9.26 CASP9 CASP8
5 cysteine-type endopeptidase activity involved in apoptotic process GO:0097153 9.13 CASP9 CASP8 CASP6

Sources for Thoracic Cancer

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....